Cargando…
The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer
SIMPLE SUMMARY: Notch signaling has been shown to mediate treatment resistance and support cancer stem cells (CSC) in luminal endocrine-resistant and triple negative breast cancers (TNBCs). The clinical development of GSIs, first-generation Notch inhibitors, has been hindered by a lack of Notch spec...
Autores principales: | Vigolo, Michele, Urech, Charlotte, Lamy, Sebastien, Monticone, Giulia, Zabaleta, Jovanny, Hossain, Fokhrul, Wyczechowska, Dorota, Del Valle, Luis, O’Regan, Ruth M., Miele, Lucio, Lehal, Rajwinder, Majumder, Samarpan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416998/ https://www.ncbi.nlm.nih.gov/pubmed/37568775 http://dx.doi.org/10.3390/cancers15153957 |
Ejemplares similares
-
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
por: Hossain, Fokhrul, et al.
Publicado: (2021) -
CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL
por: Medinger, Michael, et al.
Publicado: (2022) -
Sulindac sulfide as a non-immune suppressive γ-secretase modulator to target triple-negative breast cancer
por: Hossain, Fokhrul, et al.
Publicado: (2023) -
Obesity Modulates the Gut Microbiome in Triple-Negative Breast Cancer
por: Hossain, Fokhrul, et al.
Publicado: (2021) -
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses
por: Hossain, Fokhrul, et al.
Publicado: (2018)